SCHEMBL29564287

SCHEMBL29564287

CC(Nc1ncnc2ncc(-c3ccc(F)cc3)cc12)c1nc(C(F)(F)F)no1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 12/20 0.43
PIK3CA P42336 1/20 0.39
DYRK1A Q13627 1/20 0.37
LMNA P02545 2/20 0.37
USP2 O75604 1/20 0.37
TP53 P04637 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C19 P33261 1/20 0.37
HIF1A Q16665 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37
CCNE2 O96020 1/20 0.36
CCNE1 P24864 1/20 0.36
CDK2 P24941 1/20 0.36
GPR55 Q9Y2T6 1/20 0.36
HDAC4 P56524 2/20 0.36
HDAC1 Q13547 2/20 0.36
HDAC6 Q9UBN7 2/20 0.36
HDAC3 O15379 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22714307 1.00 EGFR (0.43) EGFRPIK3CADYRK1ALMNAUSP2
SCHEMBL22714614 0.88 EGFR (0.45) EGFRPIK3CADYRK1ALMNAUSP2
SCHEMBL29563939 0.88 EGFR (0.45) EGFRPIK3CADYRK1ALMNAUSP2
SCHEMBL24674520 0.84 EGFR (0.41) EGFRPIK3CADYRK1ALMNAUSP2
SCHEMBL29749643 0.84 EGFR (0.51) EGFRPIK3CADYRK1ACCNE2CCNE1
SCHEMBL24673915 0.84 EGFR (0.51) EGFRPIK3CADYRK1ACCNE2CCNE1
SCHEMBL29481191 0.83 EGFR (0.41) EGFRPIK3CADYRK1AHDAC4HDAC1
SCHEMBL28726511 0.83 EGFR (0.41) EGFRPIK3CADYRK1AHDAC4HDAC1
SCHEMBL22714313 0.80 EGFR (0.45) EGFRPIK3CADYRK1ALMNAUSP2
SCHEMBL22714314 0.80 EGFR (0.45) EGFRPIK3CADYRK1ALMNAUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3976609-A1 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2022-04-06 EP claimed
US-12606562-B2 Pyridopyrimidines derivatives as P2X3 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2026-04-21 US disclosed
US-20230212169-A9 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-07-06 US disclosed
US-20220235060-A1 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS CHIESI FARM SPA (IT) 2022-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220235060-A1 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS P2RX3, P2RX5, P2RX1 EGFR 1611/4885PIK3CA 302/4885DYRK1A 2677/4885
US-12606562-B2 Pyridopyrimidines derivatives as P2X3 inhibitors P2RX3, P2RX1, P2RX2 EGFR 1092/4885PIK3CA 1108/4885DYRK1A 2743/4885
US-20230212169-A9 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS P2RX3, P2RX5, P2RX1 EGFR 1611/4885PIK3CA 302/4885DYRK1A 2677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.